Eighteen months after Zoetis (NYSE: ZTS) was spun off from its parent, Pfizer (NYSE: PFE), in 2013, the animal-health company’s stock had risen a meager 5%. It’s a different story today, though. Zoetis stock continues to set new highs and is trouncing the S&P 500 index in 2017.
But can the sizzling momentum for Zoetis continue? Here are three things that could cool the stock down.